Sichuan Baili Pharmaceutical Co., Ltd.

Researchers are testing whether combining BL-B01D1, an experimental antibody-drug conjugate, with glecirasib, a targeted KRAS G12C inhibitor, can shrink tumors in adults with locally advanced or metastatic non-small cell lung cancer that carries a KRAS G12C mutation. The phase 2 …

This phase II trial tests whether the experimental drug BL-B01D1, given with or without a PD-1 antibody, can improve tumor shrinkage in people with high-risk locally advanced nasopharyngeal carcinoma, a type of throat cancer. Participants also receive standard chemotherapy drugs …

This phase III trial is testing whether adding an experimental drug called BL-B01D1 to standard maintenance therapy with a PD-1 antibody can help people with recurrent or metastatic nasopharyngeal carcinoma live longer without their cancer progressing. Participants first receive …

Researchers are testing an experimental drug called BL-M08D1 alongside standard immunochemotherapy in adults with diffuse large B-cell lymphoma. The trial enrolls about 204 people aged 18 to 75 whose cancer has at least one measurable lesion. Participants receive BL-M08D1 plus a …

Researchers are testing an experimental drug called BL-M08D1 in adults with nasopharyngeal carcinoma that has come back or spread, as well as other solid tumors. Participants receive the drug by intravenous infusion every three weeks. The trial aims to find a safe dose for furthe…

This phase Ib/II trial tests an investigational drug called BL-M08D1 in adults with recurrent or metastatic gynecological cancers and other solid tumors. The study aims to find the safest and most effective dose and to see whether the drug can shrink tumors. Participants receive …

This Phase II trial tests an experimental drug called BL-M08D1 in adults with recurrent or metastatic head and neck squamous cell carcinoma and other solid tumors. The drug is given by intravenous infusion every 3 weeks. Researchers will measure how well it shrinks tumors and how…

This study tests a new drug called BL-M11D1 in 92 adults with a type of blood cancer called myelodysplastic syndromes (MDS) that has returned or not improved with standard treatments. The goal is to find the best dose and see if the drug is safe and can shrink or eliminate cancer…

This early-stage trial is testing an investigational drug called BL-ARC002 in people with advanced gastrointestinal or other solid tumors that have spread. The main goals are to find a safe dose and to see if the drug shows any signs of shrinking tumors. Participants receive the …

This study tests an experimental drug called BL-M08D1 in adults with advanced or metastatic digestive tract tumors and other solid tumors. The goal is to find the best dose and see how well it shrinks tumors and slows disease progression. Participants receive the drug by intraven…

This phase III trial is testing whether an experimental drug called BL-M07D1 can slow or stop the growth of advanced colorectal cancer in people whose tumors have high levels of the HER2 protein and who have already tried standard chemotherapy. Participants will be randomly assig…

This early-stage trial is testing an experimental drug called SI-B036, a bispecific antibody designed to target cancer cells in a unique way. The study involves adults with locally advanced or metastatic head and neck tumors or other solid tumors. The main goals are to assess the…

This phase II trial is testing an investigational drug called BL-M09D1 in people with advanced gynecological cancers (such as ovarian, cervical, or endometrial cancer) and other solid tumors that have progressed despite standard treatment. The drug is given by intravenous infusio…

This trial is testing whether a new drug called BL-B01D1, combined with an immunotherapy that targets PD-1 and VEGF, works better than standard chemotherapy combined with the same immunotherapy for people with advanced squamous non-small cell lung cancer. About 200 adults with th…

This phase III trial is testing whether a new drug called BL-B01D1, combined with an immunotherapy (PD-1 antibody), works better than standard chemotherapy plus immunotherapy for people with advanced triple-negative breast cancer that has a specific protein (PD-L1). The study inc…

This trial is investigating whether a new combination of drugs—BL-B01D1 plus a PD-1/VEGF bispecific antibody—can work better than the current standard treatment (tislelizumab plus chemotherapy) for people with locally advanced or metastatic non-squamous non-small cell lung cancer…

This early-stage trial is testing an experimental drug called SI-B036, a bispecific antibody designed to target cancer cells in a unique way. The study will enroll about 30 adults with locally advanced or metastatic gynecological tumors or other solid tumors. The main goals are t…

This phase 1 trial is evaluating an investigational drug called SI-B036, a bispecific antibody designed to target cancer cells in a unique way. The study will enroll about 30 adults with locally advanced or metastatic urological tumors or other solid tumors. The main goals are to…

This study tests a new drug combination (BL-B01D1 plus other treatments) in 180 men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if the combination can delay cancer growth or shrink tumors. Part…

This Phase 3 trial compares a new drug called BL-M07D1 against standard chemotherapy in 404 people with HER2-expressing ovarian, fallopian tube, or peritoneal cancer that has become resistant to platinum-based treatment. Participants will receive either BL-M07D1 or one of several…